（文章来源：证券日报） 证券日报网讯 11月14日晚间，昂利康发布2025年半年度权益分派实施公告称，公司2025年半年度权益 分派方案为每10股派1元人民币现金（含税），股权登记日为2025年11月21日，除权除息日为2025年11 月24日。 ...

格隆汇11月14日丨昂利康(002940.SZ)公布2025年半年度权益分派实施公告,公司2025年半年度权益分派 方案为：以公司现有总股本剔除已回购股份561.97万 股后的1.96亿股为基数，向全体股东每股派0.1元人 民币现金（含税；扣税后，通过深股通持有股份的香港市场投资者、境外机构（含QFII、RQFII）以及 持有首发前限售股的个人和证券投资基金每股派0.09元。 本次权益分派股权登记日为：2025年11月21日，除权除息日为：2025年11月24日。 ...

格隆汇11月14日丨昂利康(002940.SZ)公布2025年半年度权益分派实施公告,公司2025年半年度权益分派 方案为：以公司现有总股本剔除已回购股份561.97万 股后的1.96亿股为基数，向全体股东每股派0.1元人 民币现金（含税；扣税后，通过深股通持有股份的香港市场投资者、境外机构（含QFII、RQFII）以及 持有首发前限售股的个人和证券投资基金每股派0.09元。 本次权益分派股权登记日为：2025年11月21日，除权除息日为：2025年11月24日。 ...

1、根据《中华人民共和国公司法》《深圳证券交易所上市公司自律监管指引 第 9 号——回购股份》等相关规定，浙江昂利康制药股份有限公司（以下简称"公 司"或"本公司"）通过回购专用证券账户（以下简称"回购专户"）持有的公司 股份不享有参与本次利润分配的权利。公司 2025 年半年度权益分派方案为：以 现 有 总 股 本 201,728,186 股 剔 除 公 司 回 购 专 户 中 股 份 5,619,700 股 后 的 196,108,486 股为基数，向全体股东每 10 股派 1.00 元人民币现金（含税），本次 不进行公积金转增股本、不送红股。公司本次现金分红的总金额=实际参与分配 的总股本×分配比例，即 19,610,848.60 元=196,108,486 股×0.10 元/股。 2、因公司回购专户上的股份不享有利润分配的权利，根据股票市值不变原 则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到每一股的比例 将减小，本次权益分派实施后计算除权除息价格时，按股权登记日的总股本折算 的每 10 股现金红利=现金分红总额÷股权登记日的总股本*10 股=19,610,848.60 元/201,728 ...

Group 1 - The core viewpoint of the news is that Anglikang's stock price increased by 5.09%, reaching 44.81 CNY per share, with a trading volume of 1.038 billion CNY and a turnover rate of 12.93%, resulting in a total market capitalization of 9.039 billion CNY [1] - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001. It was listed on October 23, 2018. The company's main business involves the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikang's main business includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, others at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of fund holdings, one fund under AVIC Fund has a significant position in Anglikang. The fund "AVIC Preferred Navigation Mixed Initiation A" (022852) held 396,100 shares in the third quarter, accounting for 3.4% of the fund's net value, ranking as the tenth largest holding [2] - The "AVIC Preferred Navigation Mixed Initiation A" fund was established on December 24, 2024, with a latest scale of 60.61 million CNY. It has achieved a return of 73.81% this year, ranking 222 out of 8147 in its category [2] - The fund manager, Wang Sen, has been in position for 2 years and 48 days, managing total assets of 2.85 billion CNY. During his tenure, the best fund return was 136.74%, while the worst was 2.83% [2]

Group 1 - The core point of the news is that Anglikang's stock price increased by 5.09%, reaching 44.81 CNY per share, with a trading volume of 1.039 billion CNY and a turnover rate of 12.94%, resulting in a total market capitalization of 9.039 billion CNY [1] - Anglikang Pharmaceutical Co., Ltd. is located in Shengzhou, Zhejiang Province, and was established on December 30, 2001. The company was listed on October 23, 2018, and its main business involves the research, production, and sales of chemical raw materials and formulations [1] - The revenue composition of Anglikang's main business includes formulations at 43.46%, raw materials at 39.82%, specialty intermediates at 12.44%, other products at 3.72%, and pharmaceutical excipients at 0.56% [1] Group 2 - From the perspective of major fund holdings, one fund under Tongtai Fund has a significant position in Anglikang. The Tongtai Health Theme Mixed A Fund (011002) held 66,200 shares in the third quarter, accounting for 4.99% of the fund's net value, making it the sixth-largest holding [2] - The Tongtai Health Theme Mixed A Fund (011002) was established on April 8, 2021, with a latest scale of 13.7512 million CNY. Year-to-date, it has achieved a return of 21.89%, ranking 4112 out of 8147 in its category; over the past year, it has returned 9.34%, ranking 5366 out of 8056; since inception, it has incurred a loss of 49.99% [2] Group 3 - The fund managers of Tongtai Health Theme Mixed A Fund (011002) are Ma Yi and Mai Jianpei. As of the report, Ma Yi has a cumulative tenure of 11 years and 241 days, with a total fund asset size of 2.718 billion CNY, achieving a best fund return of 45.64% and a worst return of -0.63% during his tenure [3] - Mai Jianpei has a cumulative tenure of 185 days, with a total fund asset size of 231 million CNY, achieving a best fund return of 21.48% and a worst return of -1.56% during his tenure [3]

Company Overview - Zhejiang Anglikang Pharmaceutical Co., Ltd. was established on December 30, 2001, and listed on October 23, 2018. The company is engaged in the research, production, and sales of chemical raw materials and preparations [1] - The main business revenue composition includes preparations (43.46%), raw materials (39.82%), specialty intermediates (12.44%), others (3.72%), and pharmaceutical excipients (0.56%) [1] Stock Performance - As of November 12, Anglikang's stock price increased by 2.02%, reaching 43.50 CNY per share, with a total market capitalization of 8.775 billion CNY [1] - Year-to-date, Anglikang's stock price has risen by 233.13%, with an 8.42% increase over the last five trading days and a 5.58% increase over the last 20 days, while it has decreased by 17.97% over the last 60 days [1] Financial Performance - For the period from January to September 2025, Anglikang reported a revenue of 1.055 billion CNY, a year-on-year decrease of 5.92%, while the net profit attributable to shareholders was 77.6899 million CNY, reflecting a year-on-year increase of 55.59% [2] - The company has distributed a total of 341 million CNY in dividends since its A-share listing, with 108 million CNY distributed over the past three years [3] Shareholder Information - As of September 30, 2025, Anglikang had 28,500 shareholders, an increase of 54.58% from the previous period, with an average of 6,493 circulating shares per shareholder, a decrease of 35.31% [2] - Notable institutional shareholders include Guangfa Medical Healthcare Stock A, which holds 3.3384 million shares, and several new entrants among the top ten circulating shareholders [3]

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 mid-term A-shares, distributing 5 yuan per 10 shares, totaling 3.448 billion yuan [1] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [2] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the development stage and has not generated revenue [3] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital [4] - Tianji Co., Ltd. reported that its controlling shareholder pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [5] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [6] 分组3 - Furi Co. reported that its subsidiary Furi New Energy is facing risks of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [7] - Wentai Technology announced that major shareholders reduced their holdings by 12.4443 million shares, completing the reduction plan [8] 分组4 - Anke Biotech signed a framework agreement for exclusive agency of PA3-17 injection, a CAR-T cell therapy product, in Greater China [9] - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6 GWh of battery cells [10] - Redik plans to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [11] 分组5 - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over three years [12] - World announced that its diamond micro-drill products for PCB processing are still in the R&D phase and have not generated revenue [13] 分组6 - Xiamen Airport reported a 1.56% year-on-year increase in passenger throughput for October [14] - New City Holdings reported a 7.65% year-on-year increase in total commercial operating revenue for October [15] - Huadong Holdings announced a 0.65% year-on-year decrease in pig sales revenue for October [15] 分组7 - Keykai Technology's controlling shareholder plans to transfer 3% of its shares [15] - Zhongyou Engineering won a joint bid for a project worth approximately 3 billion yuan in Kazakhstan [15] - Weiteng Electric plans to raise no more than 300 million yuan through a private placement for smart manufacturing projects [15]

分组1 - Midea Group announced a cash dividend distribution plan for the 2025 interim A-shares, proposing a payout of 5 yuan for every 10 shares, totaling 3.448 billion yuan [2] - Huayuan Communication is planning a change in control and will suspend trading of its stock starting November 12, 2025, for up to two trading days [3] - Shangwei New Materials reported a significant stock price increase of 1573.52% from July 9 to November 11, 2025, but its new intelligent robot business is still in the product development stage and has not yet generated revenue [4] 分组2 - Shannon Chip announced that shareholder Shenzhen Xinlianpu has pledged 1.27 million shares, accounting for 5.55% of its holdings and 0.27% of the total share capital, for financing purposes [5] - Tianji Co., Ltd. disclosed that its controlling shareholder has pledged 39.965 million shares for its own production and operation, representing 64.79% of its holdings and 7.97% of the total share capital [6] - ST Zhengping completed its stock trading situation review and will resume trading on November 12, 2025, with no significant changes in its production and operation [7] 分组3 - Furi Co., Ltd. reported that its subsidiary Furi New Energy is facing a risk of losses despite a 47.78% year-on-year increase in revenue to 168.3981 million yuan for the first three quarters of 2025 [8] - Wentai Technology announced that major shareholders have reduced their holdings by 12.4443 million shares, completing the reduction plan [9] - Anke Biotech signed a framework agreement for exclusive agency of the PA3-17 injection product in Greater China, which is a CAR-T cell therapy for certain cancers [10] 分组4 - Tongxing Technology plans to invest approximately 3.2 billion yuan in a project to produce 100,000 tons of sodium-ion battery cathode materials and 6GWh battery cells [11] - Redick is collaborating with Aoyi Technology to establish a joint venture for the development of robotic components, with a registered capital of 100 million yuan [12] - Haike New Source signed a strategic cooperation agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent over a two-year period [13] 分组5 - World announced that its diamond micro-drills for PCB processing are still in the research and testing phase, with limited revenue impact [14][15] - Huadong Holdings reported a 0.65% year-on-year decline in pig sales revenue for October [16] - Keykai Technology's controlling shareholder plans to transfer 3% of its shares through an inquiry [17]

Company Announcements - *ST Zhengping has completed the stock suspension review and will resume trading on November 12, confirming normal production and operation without significant changes [1] - Upwind New Materials is in the product development stage for its embodied intelligent robot business, which has not yet achieved mass production or revenue generation [2] - Shannon Chip Innovation's fourth largest shareholder, Shenzhen Xinlianpu, has pledged 1.27 million shares for financing purposes [3] - Qing Shui Yuan's phosphorus trichloride products are primarily used in the production of water treatment agents [4] - Midea Group announced a cash dividend plan of 5 yuan per 10 shares, totaling 3.448 billion yuan, with the record date on November 17 [4] - Huiyuan Communication is planning a change of control, leading to a stock suspension starting November 12 [5] - Shen Gong Co. has clarified that some research reports on its performance forecasts represent only analysts' personal views [6] - World is developing diamond micro-drills for PCB processing, which are still in the R&D phase [6] - Haike New Source has signed an agreement with Kunlun New Materials for the purchase of 596,200 tons of electrolyte solvent [7] - Tongxing Technology plans to invest 3.2 billion yuan in a project to produce 100,000 tons of sodium battery cathode materials and 6 GWh battery cells [8] Investments & Contracts - Zhongjin Irradiation is investing 200 million yuan to build an electronic accelerator intelligent manufacturing project [10] - Hongri Da is collaborating with Te Du Technology and Hongke Tongchuang to establish a joint venture for semiconductor packaging [10] Shareholding Changes - Jian Kai Technology's controlling shareholder Xuanzhao plans to transfer 3% of its shares through a pricing inquiry [12] - Yue Wannianqing's shareholder Hehe Investment intends to reduce its stake by up to 3% [14] Financing & Capital Increase - Weiteng Electric plans to raise up to 300 million yuan through a private placement for various manufacturing projects [22] Other Developments - Zhifei Biological has received approval for clinical trials of a vaccine for adolescents and adults [23] - Shanghai Kaibao has obtained approval for clinical trials of a drug for acute ischemic stroke [24]